Ardelyx (ARDX) Competitors $5.14 -0.06 (-1.15%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$5.24 +0.11 (+2.04%) As of 05:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. AKRO, ACLX, ACAD, VKTX, SRRK, PTCT, SWTX, MLTX, PTGX, and AAPGShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), Scholar Rock (SRRK), PTC Therapeutics (PTCT), SpringWorks Therapeutics (SWTX), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics Scholar Rock PTC Therapeutics SpringWorks Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International Ardelyx (NASDAQ:ARDX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Which has preferable earnings and valuation, ARDX or AKRO? Ardelyx has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.61M3.71-$39.14M-$0.23-22.35Akero TherapeuticsN/AN/A-$252.06M-$1.95-25.87 Do analysts rate ARDX or AKRO? Ardelyx currently has a consensus price target of $11.50, indicating a potential upside of 123.74%. Akero Therapeutics has a consensus price target of $81.57, indicating a potential upside of 61.69%. Given Ardelyx's higher possible upside, equities research analysts plainly believe Ardelyx is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ARDX or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Akero Therapeutics' return on equity of -15.19% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-14.60% -36.57% -13.42% Akero Therapeutics N/A -15.19%-13.97% Does the media prefer ARDX or AKRO? In the previous week, Ardelyx had 29 more articles in the media than Akero Therapeutics. MarketBeat recorded 38 mentions for Ardelyx and 9 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 0.76 beat Ardelyx's score of 0.70 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 5 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Akero Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in ARDX or AKRO? 58.9% of Ardelyx shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ARDX or AKRO? Ardelyx has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. SummaryArdelyx beats Akero Therapeutics on 10 of the 14 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25B$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.17%P/E Ratio-22.3519.6629.8525.14Price / Sales3.71634.78422.3397.16Price / CashN/A165.0335.9458.58Price / Book8.864.198.125.59Net Income-$39.14M$31.61M$3.26B$265.48M7 Day Performance18.71%0.95%0.68%1.22%1 Month Performance14.73%2.90%2.46%0.39%1 Year Performance-12.44%4.11%27.99%23.47% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.3377 of 5 stars$5.14-1.2%$11.50+123.7%-7.4%$1.25B$333.61M-22.3590Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionAKROAkero Therapeutics4.0212 of 5 stars$49.24-2.6%$82.50+67.5%+113.0%$4.03BN/A0.0030Insider TradeACLXArcellx2.638 of 5 stars$70.59-1.0%$111.23+57.6%+39.8%$3.93B$107.94M0.0080News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst RevisionACADACADIA Pharmaceuticals3.9858 of 5 stars$22.62-2.7%$28.13+24.3%+60.8%$3.89B$957.80M34.19510Trending NewsEarnings ReportAnalyst ForecastVKTXViking Therapeutics4.0066 of 5 stars$33.20-3.5%$86.92+161.8%-30.1%$3.87BN/A0.0020Gap UpSRRKScholar Rock4.5522 of 5 stars$37.09-4.8%$42.67+15.0%+280.6%$3.70B$33.19M0.00140News CoveragePositive NewsEarnings ReportAnalyst ForecastPTCTPTC Therapeutics4.505 of 5 stars$44.36-0.9%$65.77+48.3%+58.1%$3.55B$806.78M6.171,410Earnings ReportInsider TradeSWTXSpringWorks Therapeutics0.3711 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230MLTXMoonLake Immunotherapeutics2.6926 of 5 stars$54.47-1.1%$73.14+34.3%+20.5%$3.53BN/A0.002Earnings ReportAnalyst ForecastAnalyst RevisionPTGXProtagonist Therapeutics2.9505 of 5 stars$56.26+2.0%$66.10+17.5%+42.4%$3.42B$434.43M73.53120Earnings ReportAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.30B$134.35M0.00600Gap Up Related Companies and Tools Related Companies AKRO Competitors ACLX Competitors ACAD Competitors VKTX Competitors SRRK Competitors PTCT Competitors SWTX Competitors MLTX Competitors PTGX Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
